Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
-0.2×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.7×+4.4×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
9.5×-0.2×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
17.8×+0.5×

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×

Where this comes from

Calculated from Kymera Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's current ratio?
Kymera Therapeutics (KYMR) reported current ratio of 10.8× in Q1 2026.
How has Kymera Therapeutics's current ratio changed year-over-year?
Kymera Therapeutics's current ratio increased by 27.3% year-over-year, from 8.5× to 10.8×.
What is the long-term trend for Kymera Therapeutics's current ratio?
Over 5 years (2020 to 2025), Kymera Therapeutics's current ratio has grown at a 30.8% compound annual growth rate (CAGR), from 2.7× to 10.5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.